Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age

Bone Marrow Transplantation

Volumn 21, Issue 1, 1998, Pages 43-49

  Ringden O ^a   Remberger, M ^a   Mattsson, J ^a   Aschan, J ^a   Carlens, S ^a   Hagglund H ^a   Lonnqvist B ^a   Sparrelid, E ^a   Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Age; ATG; Bone marrow transplantation; Graft versus host disease; Leukaemia; Unrelated

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; OKT 3; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; WHOLE BODY RADIATION;

EID: 0031962547     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701067     Document Type: Article

References (36)

1. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases: published erratum appears in Blood 1990; 76: 654. Blood 1990; 75: 1728-1732.
2. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
3. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993; 119: 207-214.
4. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
5. Hows J, Bradley BA, Gore S et al on behalf of the International Marrow Unrelated Search and Transplant (IMUST) Study. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371-380.
6. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 1995; 86: 1228-1234.
7. Davies SM, Shu XO, Blazar BR et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995; 86: 1636-1642.
8. Mattsson J, Ringdén O, Aschan J et al. A low incidence of grades II to IV acute GVHD, but high mortality from infections using HLA-A, -B and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine and methotrexate. Transplant Proc 1997; 29: 735-736.
9. Bortin MM, Gale RP, Rimm AA. Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. JAMA 1981; 245: 1132-1139.
10. Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39-44.
11. Barrett AJ, Horowitz MM, Gale RP. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
12. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
13. Ringdén O, Zwaan FE, Hermans J, Gratwohl A for the Leukemia Working Party of the European Group for Bone Marrow Transplantation: European experience of bone marrow transplantation for leukemia. Transplant Proc 1987; 19: 2600-2604.
14. Carlsson B, Wallin J, Böhme J, Möller E. HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology. Hum Immunol 1987; 20: 95-113.
15. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SPP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Anttgens 1992; 39: 225-235.
16. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
17. Ringdén O, Lönnqvist B, Hägglund H et al. Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. Bone Marrow Transplant 1995; 16: 856-857.
18. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
19. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
20. Klaesson S, Ringdén O, Ljungman P et al. Does high-dose intravenous immune globin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995; 60: 1225-1230.
21. Ljungman P, Loré K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
22. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
23. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226-4235.
24. Paulin T, Ringdén O, Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987; 1: 317-328.
25. Paulin T, Ringdén O, Lönnqvist B et al. The importance of pre-bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. Scand J Infect Dis 1986; 18: 199-209.
26. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
27. Hägglund H, Boström L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.
28. Bär BMAM, DeWitte T, Schattenberg A et al. Favourable outcome of patients older than 40 years of age after transplantation with marrow grafts depleted of lymphocytes by counterflow centrifugation. Br J Haematol 1990; 74 53-60.
29. Storb R, Prentice RL, Sullivan KM el al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
30. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp Hematol 1985; 13: 1062-1067.
31. Ringdén O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094-1101.
32. Carlens S, Ringdén O, Aschan J et al. Risk-factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single center analysis. (Submitted).
33. Kolb HJ, Mittermüller J, Clemm CH et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
34. Klingemann H-G, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67: 770-776.
35. Ringdén O, Horowitz M, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57-60.
36. Rapoport AP, DiPersio JF, Martin BA et al. Patients ≥age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients